Investigational Weight Loss Drug Discussed at Obesity Society Annual Meeting


By: dhtest

Orexigen Therapeutics has announced that the investigational weight loss drug Contrave (naltrexone SR/bupropion SR) reduced the prevalence of metabolic syndrome, which is associated with an increased risk of diabetes and heart disease, by 50 percent.

Contrave is a weight loss medication that works in two places in the central nervous system. It works in the hypothalmus which controls the balance of food intake and metabolism. Contrave also works to address a second site, the reward system in the brain that controls food preference and food cravings.

According to a press release from the recent annual Obesity Society Scientific Meeting in Phoenix, Arizona, in clinical trials, Contrave showed a significant weight loss over one year of treatment (approximately 8% to 10.7% in patients completing 48 weeks of therapy) by reducing appetite, increasing metabolism, and by changing the body’s natural tendency to slow down the weight loss process. The developers expect to receive data from the first Contrave Phase 3 trials in January of 2009 and the remaining three trials by mid-next year.

Contrave is currently in Phase 3 clinical trials and in line for a late 2009 New Drug Application (NDA) submission to the FDA.

Further information can be found at

Source: The Obesity Society



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.